Linked Life Data

17431406

Source:http://linkedlifedata.com/resource/pubmed/id/17431406

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2007-5-2
pubmed:abstractText
Monoclonal antibodies are now established as a key therapeutic modality for a range of diseases. Owing to the ability of these agents to selectively target tumour cells, cancer has been a major focus of development programmes for monoclonal antibodies so far. Here, we overview trends in the clinical development and regulatory approval of monoclonal antibodies for cancer since 1980, with the aim of informing future research and development for this class of therapeutics.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1474-1776
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
349-56
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Development trends for monoclonal antibody cancer therapeutics.
pubmed:affiliation
Tufts Center for the Study of Drug Development, Tufts University, 192 South Street, Suite 550, Boston, Massachusetts 02111, USA. janice.reichert@tufts.edu
pubmed:publicationType
Journal Article, Review